News Pliant slumps on decision to pause lung disease drug trial Shares in Pliant plunged after the US biotech revealed that a safety signal led it to pause a trial of its idiopathic pulmonary fibrosis drug.
News Pliant seeks $250m offering on lung fibrosis data Buoyed by encouraging mid-stage clinical results for its idiopathic pulmonary fibrosis therapy bexotegrast, Pliant Therapeutics filed a $175million public offering, and then swiftly raised
News Streeting pledges clinical trial signups in the NHS App Millions of people in the UK will be given the opportunity to take part in clinical trials via the NHS App.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face